The 2025 ESMO annual meeting featured a urothelial carcinoma proffered paper session and a presentation by Dr. Maria De Santis discussing POTOMAC, a phase 3, randomized, open-label, trial of ...

Atezolizumab shows no significant benefit over BCG alone in treating high-risk non-muscle invasive bladder cancer, according to the ALBAN trial results.

This is the first meta-analysis comparing the overall survival of patients with limited-stage small cell bladder cancer who underwent radical surgery with platinum-based perioperative chemotherapy vs ...

The worried mum of a prisoner at a Doncaster jail has called for him to receive round the clock care after he was diagnosed ...

Results presented by AstraZeneca from its phase 3 trial of Imfinzi in patients with high-risk, non-muscle invasive bladder ...

Petros Grivas, MD, PhD, discusses the overall survival and quality-of-life findings from the JAVELIN Bladder 100 trial of ...

CG Oncology Inc. (NASDAQ:CGON) is one of the best hot stocks to invest in. On October 8, Guggenheim analyst Brad Canino ...

A phase 2 trial evaluated the combination of neoadjuvant pembrolizumab and accelerated methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy in patients with nonurothelial bladder cancers ...

When the organization now called the European Society for Medical Oncology (ESMO) opens its 50th anniversary Congress ...

Researchers in China combined findings from MRI scans with clinical features to create a new predictive model for nonmuscle-invasive bladder cancer recurrence.